Lipidomics of Alzheimer's disease

Bioanalysis

Volumn 6, Issue 4, 2014, Pages 541-561

  Touboul, David ^a   Gaudin, Mathieu ^a,b,c  

^a CNRS   (France)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; FATTY ACID; GAMMA SECRETASE INHIBITOR; GLYCEROLIPID; GLYCEROPHOSPHOLIPID; LIPID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SPHINGOLIPID; STEROL; TAU PROTEIN;

ALZHEIMER DISEASE; CELL LOSS; DATA PROCESSING; DEMENTIA; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE MARKER; ELECTROSPRAY MASS SPECTROMETRY; GENOMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; LIPID ANALYSIS; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MOLECULAR BIOLOGY; NERVE CELL; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PROTEOMICS; PUBLIC HEALTH PROBLEM; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; SENILE PLAQUE; SEPARATION TECHNIQUE; STATISTICAL ANALYSIS; THIN LAYER CHROMATOGRAPHY; TRANSCRIPTOMICS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; GLYCOLIPIDS; HUMANS; LIPIDS; MASS SPECTROMETRY; SPHINGOLIPIDS; STEROLS;

EID: 84896897706     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.346     Document Type: Review

References (146)

1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. [About a peculiar disease of the cerebral cortex]. Allgemeine Zeitschrift für Psychiatrie und psychisch-gerichtliche Medizin 64, 146-148 (1907). General Journal of Psychiatry and Psycho-Forensic Medicine.
2. Brookmeyer R, Evans DA, Hebert L et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement. 7(1) 61-73 (2011).
3. Busse A, Hensel A, Gühne U et al. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 67(12) 2176-2185 (2006). (Pubitemid 46035473)
4. Harrison J. Cognitive approaches to early Alzheimer's disease diagnosis. Med. Clin. North Am. 97(3) 425-438 (2013).
5. Teipel SJ, Grothe M, Lista S et al. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med. Clin. North Am. 97(3) 399-424 (2013).
6. Rowe CC, Villemagne VL. Amyloid imaging with PET in early Alzheimer disease diagnosis. Med. Clin. North Am. 97(3) 377-398 (2013).
7. Blennow K, Zetterberg H. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med. Clin. North Am. 97(3) 369-376 (2013).
8. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 118(1), 5-36 (2009).
9. Younkin SG. Processing of the Alzheimer's disease beta A4 amyloid precursor protein (APP). Brain Pathol. 1(4), 253-262 (1991).
10. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 368(9533), 387-403 (2006). (Pubitemid 44108123)
11. Metsaars WP, Hauw JJ, van Welse ME et al. A grading system of Alzheimer disease lesions in neocortical areas. Neurobiol. Aging 24(4), 563-572 (2003). (Pubitemid 36513704)
12. Iqbal K, Alonso Adel C, Chen S et al. Tau pathology in Alzheimer disease and other taupathies. Biochim. Biophys. Acta 1739(2-3), 198-210 (2005). (Pubitemid 40018538)
13. Arriagada PV, Growdon JH, Hedley-Whyte ET et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42(3 Pt 1), 631-639 (1992).
14. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82(4), 239-259 (1991).
15. Wolfe MS. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics 5(3), 391-398 (2008). (Pubitemid 351952492)
16. Fahrenholz F, Postina R. Alpha-secretase activation - an approach to Alzheimer's disease therapy. Neurodegener. Dis. 3(4-5), 255-261 (2006). (Pubitemid 44600312)
17. Wilcock DM, Colton CA. Anti-Ab immunotherapy in Alzheimer's disease; relevance of transgenic mouse studies to clinical trials. J. Alzheimers Dis. 15(4), 555-569 (2008).
18. Davies NM, Kehoe PG, Ben-Shlomo Y et al. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J. Alzheimers Dis. 26(4), 699-708 (2011).
19. Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J. Neurochem. 91(3), 521-536 (2004). (Pubitemid 39431148)
20. Galasko DR, Peskind E, Clark CM et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch. Neurol. 69(7) 836-841 (2012).
21. Reitz C, Tang MX, Luchsinger J et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol. 61(5) 705-714 (2004). (Pubitemid 38637688)
22. Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology:similarities and differences. Acta Neuropathol. 115(1), 5-38 (2008). (Pubitemid 50005258)
23. Piaceri I, Nacmias B, Sorbi S. Genetics of familial and sporadic Alzheimer's disease. Front. Biosci. (Elite Ed.) 5, 167-177 (2013).
24. Lazarov O, Morfini GA, Pigino G et al. Impairments infast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin1. J. Neurosci. 27(26), 7011-7020 (2007). (Pubitemid 47015908)
25. Willem M, Dewachter I, Smyth N et al. Beta-site amyloid precursor proteincleaving enzyme 1 increases amyloid deposition in brainparenchyma but reduces cerebrovascular amyloid angiopathy inaging BACE × APP[V717I] double-transgenic mice. Am. J. Pathol. 165(5), 1621-1631 (2004). (Pubitemid 39435161)
26. Rockenstein E, Mante M, Alford M et al. High beta secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J. Biol. Chem. 280(38), 32957-32967 (2005). (Pubitemid 41368345)
27. Duff K, Eckman C, Zehr C et al. Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1. Nature 383(6602), 710-713 (1996). (Pubitemid 26360645)
28. Boutajangout A, Authelet M, Blanchard V et al. Characterisation of cytoskeletal abnormalities in mice transgenic for wild type human tau and familial Alzheimer's disease mutants of APP and presenilin-1. Neurobiol. Dis. 15(1), 47-60 (2004). (Pubitemid 38134380)
29. Dettmer K, Aronov K, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 26(1), 51-78 (2007). (Pubitemid 46051813)
30. Isaac G, Bylund D, Månsson JE et al. Analysis of phosphatidyl choline and sphingomyelin molecular species from brain extracts using capillary LC-ESI-MS. J. Neurosci. Methods 128(1-2), 111-119 (2003). (Pubitemid 37013555)
31. Boselli E, Caboni MF. Supercritical carbon dioxide extraction of phospholipids from dried egg yolk without organic modifier. J. Supercritical Fluids 19(1), 45-50 (2000).
32. Daoying W, Weimin X, Xinglian X et al. Determination of intramuscular PL classes and molecular species in Gaoyou duck. Food Chem. 112(1), 150-155 (2009).
33. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226(1), 457-509 (1957).
34. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37(8), 911-917 (1959).
35. Matyash V, Liebisch G, Kurzchalia TV et al. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J. Lipid Res. 49(5), 1137-1146 (2008). • New lipid extraction method gaining popularity.
36. Wolf C, Quinn PJ. Lipidomics: practical aspects and applications. Prog. Lipid Res. 47(1), 15-36 (2008). (Pubitemid 350216620)
37. Touchstone JC. Thin-layer chromatographic procedures for lipid separation. J. Chromatogr. B 671, 169-195 (1995).
38. Fuchs B, Süb R, Teuber K et al. Lipid analysis by thin-layer chromatography - a review of the current state. J. Chromatogr. A 1218(19), 2754-2774 (2011).
39. Bayir H, Tyurin VA, Tyurina YY et al. Selective early cardiolipin peroxidation after traumatic brain injury: an oxidative lipidomics analysis. Ann. Neurol. 62(2), 154-169 (2007). (Pubitemid 47546501)
40. Gutnikov G. Fatty acid lipid profiles. J. Chromatogr. B 671(1-2), 71-89 (1995).
41. Masson ME, Waller GR. Dimethoxypropane induced transesterification of fats and oils in preparation of methyl esters for gas chromatographic analysis. Anal. Chem. 36(3) 583-586 (1964).
42. Douglas DJ. Linear quadrupoles in mass spectrometry. Mass Spectrom. Rev. 28(6), 937-960 (2009).
43. Vestal ML, Campbell JM. Tandem time-of-flight mass spectrometry. Meth. Enzymol. 402, 79-108 (2005). (Pubitemid 43053126)
44. Han X, Gross RW. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 24(3), 367-412 (2005). (Pubitemid 40665798)
45. Karas M, Bachman D, Bahr U et al. Matrix-assisted ultraviolet laser desorption of non-volatile compounds. Int. J. Mass Spectrom. Ion Proc. 78, 53-68 (1987).
46. Tanaka K, Waki H, Ido Y et al. Protein and polymer analyses up to m/z 100 000 by laser ionization time-of flight mass spectrometry. Rapid Commun. Mass Spectrom. 2(20), 151-153 (1988).
47. Shevchenko A, Loboda A, Shevchenko A et al. MALDI quadrupole time-of-flight mass spectrometry: a powerful tool for proteomic research. Anal. Chem. 72(9), 2132-2141 (2000). (Pubitemid 30316592)
48. Fuchs B, Schiller J. MALDI-TOF MS analysis of lipids from cells, tissues and body fluids. Subcell. Biochem. 49, 541-565 (2008).
49. Ståhlman M, Ejsing CS, Tarasov K et al. High-throughput shotgun lipidomics by quadrupole time-of-flight mass spectrometry. J. Chromatogr. B 877, 2664-2672(2009).
50. Fenn JB, Mann M, Kai C et al. Electrospray ionization-principles and practice. Mass Spectrom. Rev. 9, 37-70 (1990).
51. Graeve M, Janssen DJ. Improved separation and quantification of neutral and polar lipid classes by HPLC-ELSD using a monolithic silica phase: application to exceptional marine lipids. Chromatogr. B Anal. Technol. Biomed. Life Sci. 877(20-21), 1815-1819 (2009).
52. Imbert L, Gaudin M, Libong L et al. Comparison of electrospray ionization, atmospheric pressure chemical ionization and atmospheric pressure photoionization for a lipidomic analysis of Leishmania donovani. J. Chrom. A 1242, 75-83 (2012).
53. Roy S, Delobel A, Gaudin K et al. Liquid chromatography on porous graphitic carbon with atmospheric pressure photoionization mass spectrometry and tandem mass spectrometry for the analysis of glycosphingolipids. J. Chromatogr. A 1117, 154-162 (2006).
54. Gaudin M, Imbert L, Libong D et al. Atmospheric pressure photoionization as a powerfull tool for large-scale lipidomic studies. J. Am. Soc. Mass Spectrom. 23(5), 869-879 (2012).
55. Laaksonen R, Katajamaa M, Päivä H et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 1, e97 (2006).
56. Want EL, Coen M, Masson P et al. Ultra performance liquid chromatography-mass spectrometry profiling of bile acid metabolites in biofluids: application to experimental toxicology studies. Anal. Chem. 82(12), 5282-5289 (2010).
57. Plumb RS, Rainville PD, Potts WB et al. Application of ultra performance liquid chromatography-mass spectrometry to profiling of rat and dog bile. J. Proteome Res. 8(5), 2495-2500 (2009).
58. Miller TM, Donnelly MK, Crago EA et al. Rapid, simultaneous quantitation of mono and dioxygenated metabolites of arachidonic acid in human CSF and rat brain. J. Chromatogr. B 877(31), 3991-4000 (2009).
59. Huang Q, Yin P, Wang J et al. Method for liver tissue metabolic profiling study and its application in type 2 diabetic rats based on ultra performance liquid chromatography-mass spectrometry. J. Chromatogr. B879(13-14), 961-967 (2011).
60. Bou Khalil M, Hou W, Zhou H et al. Lipidomics era: accomplishments and challenges. Mass Spectrom. Rev. 29(6), 877-929 (2010). •• Extensive review that should be read by any newcomer in lipidomics.
61. Perry RH, Cooks RG, Noll RJ. Orbitrap mass spectrometry: instrumentation, ion motion and applications. Mass Spectrom. Rev. 27(6), 661-699 (2008).
62. Ayciriex S, Regazzetti A, Gaudin M et al. Development of a novel method for quantification of sterols and oxysterols by UPLC-ESI-HRMS: application to a neuroinflammation rat model. Anal. BioAnal. Chem. 404(10), 3049-3059 (2012).
63. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J. Proteome Res. 6(2), 469-479 (2007). (Pubitemid 46340151)
64. Jiang X, Sidhu R, Porter FD et al. A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. J. Lipid Res. 52(7), 1435-1445 (2011).
65. Touboul D, Roy S, Germain DP et al. Fast fingerprinting by MALDI-TOF mass spectrometry of urinary sediment glycosphingolipids in Fabry disease. Anal. BioAnal. Chem. 382(5), 1209-1216 (2005). (Pubitemid 40983110)
66. Svennerholm L, Vanier MT, Månsson JE. Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. J. Lipid Res. 21(1), 53-64 (1980). (Pubitemid 10120438)
67. Dekker N, van Dussen L, Hollak CE et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 118(16), e118-e127 (2011).
68. Li F, Qin X, Chen H et al. Lipid profiling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun. Mass Spectrom. 27(1), 24-34 (2013).
69. Schäfer KC, Balog J, Szaniszló T et al. Real time analysis of brain tissue by direct combination of ultrasonic surgical aspiration and sonic spray mass spectrometry. Anal. Chem. 83(20), 7729-7735 (2011).
70. Takats Z, Denes J, Kinross J. Identifying the margin: a new method to distinguish between cancerous and noncancerous tissue during surgery. Future Oncol. 8(2), 113-116 (2012).
71. Fahy E, Subramanian S, Brown HA et al. A comprehensive classification system for lipids. J. Lipid Res. 46(5), 839-861 (2005).
72. Fahy E, Subramaniam S, Murphy RC et al. Update of the LIPID MAPS comprehensive classification system for lipids. J. Lipid Res. 50, S9-S14 (2009). •• Reference paper on lipid classification and nomenclature.
73. Wellington CL. Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. Clin. Genet. 66, 1-16 (2004). (Pubitemid 38960816)
74. Hirsh-Reinshagen V, Burgess BL, Wellington CL. Why lipids are important in Alzheimer disease? Mol. Cell Biochem. 326, 121-129 (2009).
75. Nagy Z, Esiri M, Jobst KA et al. Influence of the apolipoprotein Egenotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 69, 757-761 (1995).
76. Sunderland T, Mirza N, Putnam KT et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol. Psychiatry 56, 670-676 (2004). (Pubitemid 39446849)
77. Liao L, Cheng D, Wang J et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J. Biol. Chem. 279, 37061-37068 (2004). (Pubitemid 39129056)
78. Namba Y, Tomonaga M, Kawasaki H et al. Apolipoprotein E immunoreactivity in cerebralamyloid deposits and neurofibrilliary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jacob disease. Brain Res. 541, 163-166 (1991).
79. Castellano JM, Kim J, Stewart FR et al. Human apoE isoforms differentially regulate brain amyloid-{beta} peptide clearance. Sci. Transl. Med. 3, 89ra57 (2011).
80. Bales KR, Verina T, Dodel R. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17, 263-264 (1997).
81. Fraser T, Tayler H, Love S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem. Res. 35(3), 503-513 (2010).
82. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8(5), 349-361 (2008). •• Review describing the increasingly recognized role of lipids as signaling molecules. (Pubitemid 351595216)
83. Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim. Biophys. Acta 1801(12), 1260-1273 (2010).
84. Reich EE, Markesbery WR, Roberts LJ et al. Brain regional quantificationof F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's Disease. Am. J. Pathol. 158, 293-297 (2001). (Pubitemid 32096495)
85. Lukiw WJ, Cui JG, Marcheselli VL et al. A role fordocosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 115, 2774-2783 (2005). (Pubitemid 41434404)
86. Oster T, Pillot T. Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice. Biochim. Biophys. Acta 1801(8), 791-798 (2010).
87. Gattaz WF, Maras A, Cairns NJ et al. Decreased phospholipase A2 activity in Alzheimer brains. Biol. Psychiatry 37(1), 13-17 (1995).
88. Chalbot S, Zetterberg H, Blennow K et al. Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease. Clin. Chem. 55(12), 2171-2179 (2009).
89. Schaeffer EL, De-Paula VJ, da Silva ER et al. Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein. J. Neural Transm. 118(9) 1273-1279 (2011).
90. Burgess BL, McIsaac SA, Naus KE et al. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A-beta in plasma. Neurobiol. Dis. 24(1), 114-127 (2006). (Pubitemid 44416212)
91. Reitz C, Tang MX, Luchsinger J et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol. 61(5), 705-714 (2004). (Pubitemid 38637688)
92. Nitsch RM, Blusztajn JK, Pittas AG et al. Evidence for a membrane defect in Alzheimer's disease brain. Proc. Natl Acad. Sci. USA 89, 1671-1675 (1992).
93. Grimm MO, Grösgen S, Riemenschneider M et al. From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J. Chromatogr. A 1218, 7713-7722 (2010).
94. Gaudin M, Panchal M, Auzeil N et al. Choline-containing phospholipids in microdissected human Alzheimer's disease brain senile plaques versus neuropil. Bioanalysis 4(17), 2153-2159 (2012).
95. Han X, Holtzman DM, McKeel DW Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and inanimal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem.77, 1168-1180 (2001). (Pubitemid 32467071)
96. Wood PL, Mankidy R, Ritchie S et al. Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J. Psychiatry Neurosci. 35, 59-62 (2010).
97. Goodenowe DB, Cook LL, Liu J et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 48, 2485-2498 (2007). (Pubitemid 350058760)
98. Grimm MOW, Kuchenbecker J, Rothhaar TL et al. Plasmalogen synthesis is regulated by alkyl dihydroxyacetone phosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer's disease. J. Neurochem. 116, 916-925 (2011).
99. Yao JK, Wengenack TM, Curran GL et al. Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem. Res. 34(1), 102-108 (2009).
100. Bader Lange ML, Cenini G, Piroddi M et al. Loss of phospholipid asymmetry and elevated apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol. Dis. 29(3), 456-464 (2008).
101. Landman N, Jeong SY, Shin SY et al. Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc. Natl Acad. Sci. USA 103, 19524-19529 (2006). (Pubitemid 46026064)
102. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat. Rev. 12, 284-296 (2011). •• The complex relationship between Alzheimer's disease and lipid metabolism highlights that cholesterol is not the only lipid partner of great interest in this disease.
103. Cai D, Zhong M, Wang R et al. Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc. Natl Acad. Sci. USA 106, 1936-1940 (2006). (Pubitemid 43228796)
104. Guan ZZ, Söderberg M, Sindelar P et al. Content and fatty acid composition of cardiolipin in the brain of patients with Alzheimer's disease. Neurochem. Int. 25(3), 295-300 (1994). (Pubitemid 24282431)
105. Puglielli L, Ellis BC, Saunders AJ et al. Ceramide stabilizes b-site amyloid precursor protein cleaving enzyme 1 and promotes amyloid b-peptide biogenesis. J. Biol. Chem. 278, 19777-19783 (2003). (Pubitemid 36799164)
106. Haughey NJ, Bandaru VVR, Bae M et al. Roles for dysfunctional sphingolipid metabolism inAlzheimer's disease neuropathogenesis. Biochim. Biophys. Acta 1801(8), 878-886 (2010).
107. Mielke MM, Lyketsos CG. Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? Neuromol. Med. 12, 331-340 (2010).
108. Han X, Holtzman DM, McKeel DW Jr, Morris JC et al. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 82, 809-818 (2002). • One of the first studies by shotgun lipidomics revealing sphingolipid alterations in Alzheimer's disease.
109. He X, Huang Y, Li B et al. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol. Aging 31, 398-408 (2010).
110. Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease. Neurochem. Res. 32, 845-856 (2007). (Pubitemid 46481322)
111. Satoi H, Tomimoto H, Ohtani R et al. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 130, 657-666 (2005). (Pubitemid 39601439)
112. Mielke MM, Bandaru VVR, Haughey NJ et al. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol. Aging 31, 17-24 (2010).
113. Mielke MM, Haughey NJ, Bandaru VVR et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 6, 378-385 (2010).
114. Han X, Rozen S, Boyle SH et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 6(7), e21643v (2011).
115. Mielke MM, Maetzler W, Haughey NJ et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS ONE. 8(9), e73094 (2013).
116. Grimm MOW, Grimm HS, Pätzold AJ et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-b andpresenilin. Nat. Cell Biol. 7, 1118-1123 (2005).
117. Pettegrew JW, Panchalingam K, Hamilton RL et al. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 26, 771-782 (2001). (Pubitemid 32845968)
118. Bandaru VVR, Troncoso J, Wheeler D et al. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol. Aging 30, 591-599 (2009).
119. Cutler RG, Kelly J, Storie K et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 2070-2075 (2004). (Pubitemid 38229016)
120. Han X, Cheng H, Fryer JD et al. Novel role for apolipoprotein E in the central nervous system. modulation of sulfatide content. J. Biol. Chem. 278, 8043-8051 (2003). (Pubitemid 36800543)
121. Han X, Fagan AM, Cheng H et al. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann. Neurol. 54, 115-118 (2003).
122. Kracun I, Kalanj S, Cosovic C, Talan-Hranilovic J. Brain gangliosides in Alzheimer's disease. J. Hirnforsch. 31(6), 789-793 (1990).
123. Yamamoto N, Matsubara T, Sato T et al. Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid b-protein fibrillogenesis. Biochim. Biophys. Acta 1778, 2117-2126 (2008).
124. Matsuzaki K, Kato K, Yanagisawa K. Ab polymerization through interaction with membrane gangliosides. Biochim. Biophys. Acta 868-877 (2010) (1801).
125. Matsuoka Y, Saito M, LaFrancois J et al. Therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to b-amyloid. J. Neurosci.23, 29-33 (2003). (Pubitemid 36050401)
126. Taylor DR, Hooper NM. Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-b proteins. Sem. Cell. Devel. Biol. 18, 638-648 (2007). (Pubitemid 350030896)
127. Simons M, Keller P, De Strooper B et al. Cholesterol depletion inhibits thegeneration of b-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 6460-6464 (1998). (Pubitemid 28249035)
128. Mori T, Paris D, Town T et al. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J. Neuropathol. Exp. Neurol. 60, 778-785 (2001). (Pubitemid 32678258)
129. Burns MP, Noble WJ, Olm V et al. Co-localization ofcholesterol, apolipoprotein E and fibrillar Ab in amyloid plaques. Mol. Brain Res. 110, 119-125 (2003). (Pubitemid 36165049)
130. Panchal M, Loeper J, Cossec JC et al. Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry. J. Lipid Res. 51(3), 598-605 (2010). • First study unambiguously evaluating the lipid content of the senile plaque.
131. Martins IC, Kuperstein I, Wilkinson H et al. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27, 224-233 (2008).
132. Bryleva EY, Rogers MA, Chang CCY et al. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl Acad. Sci. USA 107, 3081-3086 (2010).
133. Silva T, Teixeira J, Remião F, Borges F. Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways. Angew. Chem. Int. Ed. Engl. 52(4), 1110-1121 (2013).
134. Gamba P, Testa G, Sottero B et al. The link between altered cholesterol metabolism and Alzheimer's disease. Ann. NY Acad. Sci. 1259, 54-64 (2012).
135. Arlt S, Müller-Thomsen T, Beisiegel U. Use of vitamin C and E in the treatment of Alzheimer's disease. Drug Dev. Res. 56, 452-457 (2002). (Pubitemid 35168322)
136. Annweiler C, Llewellyn DJ, Beauchet O. Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimer Dis. 33(3), 659-674 (2013).
137. Sato Y, Honda Y, Hayashida N et al. Vitamin K deficiency and osteopenia in elderly women with Alzheimer's disease. Arch. Phys. Med. Rehabil. 86(3), 576-581 (2005). (Pubitemid 40326644)
138. Ono K, Yamada M. Vitamin A and Alzheimer's disease. Geriatr. Gerontol. Int. 12(2), 180-188 (2012).
139. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol. 29(1) 26-32 (2001).
140. Frisoni GB, Bocchetta M, Chételat G et al. Imaging markers for Alzheimer disease: which vs how. Neurology 81(5), 487-500 (2013).
141. Stoeckli M, Staab D, Staufenbiel M et al. Molecular imaging of amyloid beta peptides in mouse brain sections using mass spectrometry. Anal. Biochem. 311(1), 33-39 (2002). (Pubitemid 35463486)
142. Hutchinson RW, Cox AG, McLeod CW et al. Imaging and spatial distribution of beta-amyloid peptide and metal ions in Alzheimer's plaques by laser ablation-inductively coupled plasma mass spectrometry. Anal. Biochem. 346(2), 225-233 (2005). (Pubitemid 41550254)
143. Yuki D, Sugiura Y, Zaima N et al. Hydroxylated and non-hydroxylated sulfatide are distinctly distributed in the human cerebral cortex. Neuroscience 193, 44-53 (2011).
144. Lazar AN, Bich C, Panchal M et al. Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol. 125(1), 133-144 (2013).
145. Hornung E, Korfei M, Pernstich C et al. Specific formation of arachidonic acid and eicosapentaenoic acid by a front-end delta5-desaturase from Phytophthora megasperma. Biochim. Biophys. Acta 1686(3), 181-189 (2005). (Pubitemid 40039145)
146. Castro-Perez JM, Kamphorst J, DeGroot J et al. Comprehensive LC-MSE lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J. Proteome Res. 9(5), 2377-2389 (2010).